Key Drivers
- High profitability
- Heavy leverage
- Strong liquidity
AIAI Summary
Zoetis has pivoted from a defensive cash-generator to a growth-by-innovation and M&A story—successful commercialization/integration of biologics and genomics (e.g., Neogen) is the critical catalyst for multiple expansion, while high leverage and reputational/regulatory risks (notably Librela adoption) make execution the decisive investment risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High profitability
- •Heavy leverage
- •Strong liquidity
ZTS delivers exceptional margins, ROE and free cash flow with strong liquidity, but is heavily leveraged, carries large intangibles/OCI exposure, and trades at premium multiples.
Price Behavior
Key Price Behavior Insights:
- •Downtrend momentum
- •Support holding
- •Resistance band
Over the last month ZTS dropped roughly 10% into short-term support near $115–$116, leaving resistance at $128–$131 and elevated volatility such that a decisive break below $115 would confirm continuation while a sustained move above ~$128–$129 would signal a trend change.
Price swung from ~$131 to ~$115 in three weeks, implying elevated short-term volatility
Sentiment & News
Key News Insights:
- •Analyst buy consensus
- •Institutional accumulation
- •FDA post‑market risk
Zoetis draws strong analyst buy ratings and notable institutional accumulation amid momentum/value interest, but near-term FDA post‑marketing results for Librela/Solensia and mixed fund trimming pose downside risk.
Overall sentiment is constructive and could support upside if FDA results are benign, but short‑term volatility is likely given the product safety catalyst
Similar Companies in Healthcare
Other companies in the same sector with AI ratings